CN102639693B - 乳动脉衍生细胞及在组织修复和再生中的应用方法 - Google Patents
乳动脉衍生细胞及在组织修复和再生中的应用方法 Download PDFInfo
- Publication number
- CN102639693B CN102639693B CN201080055145.1A CN201080055145A CN102639693B CN 102639693 B CN102639693 B CN 102639693B CN 201080055145 A CN201080055145 A CN 201080055145A CN 102639693 B CN102639693 B CN 102639693B
- Authority
- CN
- China
- Prior art keywords
- cell
- artery
- imac
- internal mammary
- mammary artery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000001349 mammary artery Anatomy 0.000 title claims abstract description 95
- 238000000034 method Methods 0.000 title claims abstract description 54
- 230000017423 tissue regeneration Effects 0.000 title description 5
- 238000011069 regeneration method Methods 0.000 title description 2
- 241000124008 Mammalia Species 0.000 claims abstract description 46
- 238000000926 separation method Methods 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims description 312
- 210000001367 artery Anatomy 0.000 claims description 36
- 230000014509 gene expression Effects 0.000 claims description 34
- 230000029087 digestion Effects 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 24
- 102000004190 Enzymes Human genes 0.000 claims description 23
- 108090000790 Enzymes Proteins 0.000 claims description 23
- 229940088598 enzyme Drugs 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 23
- -1 CD62p Proteins 0.000 claims description 16
- 108010035532 Collagen Proteins 0.000 claims description 15
- 102000008186 Collagen Human genes 0.000 claims description 15
- 239000002458 cell surface marker Substances 0.000 claims description 15
- 229920001436 collagen Polymers 0.000 claims description 15
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 14
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 13
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 13
- 238000011534 incubation Methods 0.000 claims description 13
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 12
- 210000003725 endotheliocyte Anatomy 0.000 claims description 12
- 102100037241 Endoglin Human genes 0.000 claims description 11
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 claims description 11
- 102100026966 Thrombomodulin Human genes 0.000 claims description 11
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims description 10
- 102100040120 Prominin-1 Human genes 0.000 claims description 10
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 10
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 8
- 102100024210 CD166 antigen Human genes 0.000 claims description 8
- 102100032912 CD44 antigen Human genes 0.000 claims description 8
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 8
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 claims description 8
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 8
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims description 8
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims description 8
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 8
- 102100025304 Integrin beta-1 Human genes 0.000 claims description 8
- 102100033000 Integrin beta-4 Human genes 0.000 claims description 8
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 8
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims description 8
- 230000036961 partial effect Effects 0.000 claims description 8
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 7
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims description 7
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 7
- 102100035721 Syndecan-1 Human genes 0.000 claims description 7
- 238000013467 fragmentation Methods 0.000 claims description 7
- 238000006062 fragmentation reaction Methods 0.000 claims description 7
- 210000003684 theca cell Anatomy 0.000 claims description 7
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims description 6
- 108060005980 Collagenase Proteins 0.000 claims description 6
- 102000029816 Collagenase Human genes 0.000 claims description 6
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims description 6
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 6
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 6
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 6
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 6
- 229960002424 collagenase Drugs 0.000 claims description 6
- 108010007093 dispase Proteins 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 5
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 claims description 4
- 102000008790 VE-cadherin Human genes 0.000 claims description 4
- 210000001789 adipocyte Anatomy 0.000 claims description 4
- 230000003321 amplification Effects 0.000 claims description 4
- 108010018828 cadherin 5 Proteins 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 230000002107 myocardial effect Effects 0.000 claims description 2
- 101100127285 Drosophila melanogaster unc-104 gene Proteins 0.000 description 117
- 230000004069 differentiation Effects 0.000 description 37
- 210000001519 tissue Anatomy 0.000 description 36
- 239000001963 growth medium Substances 0.000 description 30
- 108010082117 matrigel Proteins 0.000 description 30
- 230000012010 growth Effects 0.000 description 20
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 18
- 239000002953 phosphate buffered saline Substances 0.000 description 18
- 210000000130 stem cell Anatomy 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 15
- 238000011081 inoculation Methods 0.000 description 15
- 239000007788 liquid Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 12
- 238000000684 flow cytometry Methods 0.000 description 12
- 239000003550 marker Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 11
- 235000011089 carbon dioxide Nutrition 0.000 description 11
- 238000004113 cell culture Methods 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 239000000975 dye Substances 0.000 description 10
- 238000004043 dyeing Methods 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 102000013275 Somatomedins Human genes 0.000 description 9
- 230000003750 conditioning effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 8
- 241000508269 Psidium Species 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 8
- 210000002889 endothelial cell Anatomy 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 239000007943 implant Substances 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 230000003068 static effect Effects 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 235000003170 nutritional factors Nutrition 0.000 description 7
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 7
- 238000009987 spinning Methods 0.000 description 7
- 230000004862 vasculogenesis Effects 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102000012422 Collagen Type I Human genes 0.000 description 6
- 108010022452 Collagen Type I Proteins 0.000 description 6
- 102000003729 Neprilysin Human genes 0.000 description 6
- 108090000028 Neprilysin Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000002308 calcification Effects 0.000 description 6
- 210000004413 cardiac myocyte Anatomy 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 230000011164 ossification Effects 0.000 description 6
- 239000012679 serum free medium Substances 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 5
- 102100034864 Homeobox protein Hox-D9 Human genes 0.000 description 5
- 101001019766 Homo sapiens Homeobox protein Hox-D9 Proteins 0.000 description 5
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 210000004351 coronary vessel Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000002493 microarray Methods 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 4
- 101710153593 Albumin A Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- 210000000709 aorta Anatomy 0.000 description 4
- 239000003124 biologic agent Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000001523 electrospinning Methods 0.000 description 4
- 230000009762 endothelial cell differentiation Effects 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000002831 pharmacologic agent Substances 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000008467 tissue growth Effects 0.000 description 4
- BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical compound [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 description 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 3
- 102100022749 Aminopeptidase N Human genes 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 3
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010036395 Endoglin Proteins 0.000 description 3
- 101800004490 Endothelin-1 Proteins 0.000 description 3
- 102400000686 Endothelin-1 Human genes 0.000 description 3
- 102100023688 Eotaxin Human genes 0.000 description 3
- 206010015548 Euthanasia Diseases 0.000 description 3
- 101150021185 FGF gene Proteins 0.000 description 3
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 3
- 102000008857 Ferritin Human genes 0.000 description 3
- 108050000784 Ferritin Proteins 0.000 description 3
- 238000008416 Ferritin Methods 0.000 description 3
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 3
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 3
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 3
- 101000572989 Homo sapiens POU domain, class 3, transcription factor 3 Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 206010029113 Neovascularisation Diseases 0.000 description 3
- 102100028762 Neuropilin-1 Human genes 0.000 description 3
- 108090000772 Neuropilin-1 Proteins 0.000 description 3
- 102000002131 PAS domains Human genes 0.000 description 3
- 108050009469 PAS domains Proteins 0.000 description 3
- 102100026456 POU domain, class 3, transcription factor 3 Human genes 0.000 description 3
- 108010082093 Placenta Growth Factor Proteins 0.000 description 3
- 102100035194 Placenta growth factor Human genes 0.000 description 3
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 3
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 3
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 3
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 3
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 3
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 3
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 3
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 229960003624 creatine Drugs 0.000 description 3
- 239000006046 creatine Substances 0.000 description 3
- 238000005138 cryopreservation Methods 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 108091022862 fatty acid binding Proteins 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 102100036537 von Willebrand factor Human genes 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 2
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- 102100029761 Cadherin-5 Human genes 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101001053263 Homo sapiens Insulin gene enhancer protein ISL-1 Proteins 0.000 description 2
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 2
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 2
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 101150088608 Kdr gene Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 206010054949 Metaplasia Diseases 0.000 description 2
- 101100366227 Mus musculus Sox11 gene Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 102100029529 Thrombospondin-2 Human genes 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000012574 advanced DMEM Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 230000000489 anti-atherogenic effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000011694 lewis rat Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000015689 metaplastic ossification Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000003507 refrigerant Substances 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 210000003752 saphenous vein Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108010060887 thrombospondin 2 Proteins 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- CPBJMKMKNCRKQB-UHFFFAOYSA-N 3,3-bis(4-hydroxy-3-methylphenyl)-2-benzofuran-1-one Chemical compound C1=C(O)C(C)=CC(C2(C3=CC=CC=C3C(=O)O2)C=2C=C(C)C(O)=CC=2)=C1 CPBJMKMKNCRKQB-UHFFFAOYSA-N 0.000 description 1
- JKYKXTRKURYNGW-UHFFFAOYSA-N 3,4-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(O)=C(O)C(S(O)(=O)=O)=C2 JKYKXTRKURYNGW-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000010825 Actinin Human genes 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 101100208237 Bos taurus THBS2 gene Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000021479 Cardiovascular injury Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000016216 Choristoma Diseases 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 102100032759 Cysteine-rich motor neuron 1 protein Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
- 101000942095 Homo sapiens Cysteine-rich motor neuron 1 protein Proteins 0.000 description 1
- 101000994378 Homo sapiens Integrin alpha-3 Proteins 0.000 description 1
- 101000645293 Homo sapiens Metalloproteinase inhibitor 3 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 101000825086 Homo sapiens Transcription factor SOX-11 Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102100032819 Integrin alpha-3 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 108700041567 MDR Genes Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 1
- 208000009857 Microaneurysm Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042957 Systolic hypertension Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010014401 TWEAK Receptor Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 102100022415 Transcription factor SOX-11 Human genes 0.000 description 1
- 102100031013 Transgelin Human genes 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100028786 Tumor necrosis factor receptor superfamily member 12A Human genes 0.000 description 1
- 102100023341 Ubiquitin-40S ribosomal protein S27a Human genes 0.000 description 1
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000001980 alanyl group Chemical group 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 108010048527 glycerol-2-phosphatase Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005119 human aortic smooth muscle cell Anatomy 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000012804 iterative process Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108010011179 ribosomal protein S27a Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
- C12N5/0692—Stem cells; Progenitor cells; Precursor cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
抗体 | 制造商 | 目录号 |
CD34 | BD Pharmingen | 555821 |
CD44 | BD Pharmingen | 555478 |
CD45R | BD Pharmingen | 555489 |
CD117 | BD Pharmingen | 340529 |
CD141 | BD Pharmingen | 559781 |
CD31 | BD Pharmingen | 555446 |
CD133 | Miltenyi Biotech | 120-001-243 |
SSEA4 | R&D Systems | FAB1435P |
CD105 | SantaCruz Biotech | SC-21787 |
CD104 | BD Pharmingen | 555720 |
CD166 | BD Pharmingen | 559263 |
CD29 | BD Pharmingen | 555442 |
IgG-FITC | BD Pharmingen | 555748 |
IgG-PE | BD Pharmingen | 555749 |
CD34 | BD Pharmingen | 555821 |
CD44 | BD Pharmingen | 555478 |
CD45R | BD Pharmingen | 555489 |
CD117 | BD Pharmingen | 340529 |
CD141 | BD Pharmingen | 559781 |
CD31 | BD Pharmingen | 555446 |
CD49c | BD Pharmingen | 556025 |
CD73 | BD Pharmingen | 550257 |
CD90 | BD Pharmingen | 555596 |
HLA-I | BD Pharmingen | 555553 |
HLA-II | BD Pharmingen | 555558 |
CD133 | Miltenyi Biotech | 120-001-243 |
SSEA4 | R&D Systems | FAB1435P |
CD105 | SantaCruz Biotech | SC-21787 |
CD104 | BD Pharmingen | 555720 |
CD166 | BD Pharmingen | 559263 |
CD29 | BD Pharmingen | 555442 |
CD24 | BD Pharmingen | 555428 |
CD56 | AbCAM | MEM188 |
CD138 | BD Pharmingen | 550805 |
E-钙黏着蛋白 | BD Pharmingen | 612130 |
IgG-FITC | BD Pharmingen | 555748 |
IgG-PE | BD Pharmingen | 555749 |
细胞类型 | 抗体 | 细胞类型表达 | iMAC表达 |
内皮细胞祖细胞 | CD34 | 阳性 | 阴性 |
CD133 | 阳性 | 阴性 | |
CD45 | 阳性 | 阴性 | |
内皮细胞 | VE钙黏着蛋白 | 阳性 | 阴性 |
KDR/Flk1 | 阳性 | 阴性 | |
CD31 | 阳性 | 阴性 | |
CD104 | 阳性 | 阴性 | |
平滑肌细胞 | CD141 | 阳性 | 阴性 |
间充质干细胞 | CD10 | 阳性 | 阴性 |
CD29 | 阳性 | 阳性 | |
CD44 | 阳性 | 阳性 | |
CD73 | 阳性 | 阳性 | |
CD105 | 阳性 | 阴性 | |
CD166 | 阳性 | 阳性 | |
其他 | CD15 | 阳性 | 阴性 |
CD23 | 阳性 | 阴性 | |
CD24 | 阳性 | 阴性 | |
CD62p | 阳性 | 阴性 | |
CD73 | 阳性 | 阳性 | |
CD80 | 阳性 | 阴性 |
CD86 | 阳性 | 阴性 | |
CD117 | 阳性 | 阴性 | |
CD138 | 阳性 | 阴性 | |
HLA 1 | 阳性 | 阳性 | |
HLA 2 | 阳性 | 阴性 |
UniGene | 说明 |
Hs.311640 | 核糖体蛋白S27a |
Hs.525622 | V-akt鼠胸腺瘤病毒癌基因同源物1 |
Hs.1239 | 丙氨酰(膜)氨基肽酶,CD13 |
Hs.303649 | 趋化因子(C-C模体)配体2 |
Hs.532655 | 肝配蛋白-A2 |
Hs.516656 | 肝配蛋白-A3 |
Hs.76753 | 内皮糖蛋白(Osler-Rendu-Weber综合征1) |
Hs.468410 | 内皮细胞PAS结构域蛋白1 |
Hs.284244 | 成纤维细胞生长因子2(碱性) |
Hs.1420 | 成纤维细胞生长因子受体3 |
Hs.509554 | 低氧诱导因子1 |
Hs.512234 | 白细胞介素6(干扰素,β2) |
Hs.479756 | 激酶插入结构域受体 |
Hs.513617 | 基质金属肽酶2 |
Hs.131704 | 神经毡蛋白1 |
Hs.252820 | 胎盘生长因子 |
Hs.77274 | 纤溶酶原激活物,尿激酶 |
Hs.371147 | 血小板反应蛋白2 |
Hs.522632 | TIMP金属肽酶抑制剂1 |
Hs.652397 | TIMP金属肽酶抑制剂3 |
Hs.355899 | 肿瘤坏死因子受体超家族,成员12A |
Hs.631558 | 1型肌钙蛋白T(骨骼,慢) |
Hs.78781 | 血管内皮细胞生长因子B |
Hs.435215 | 血管内皮细胞生长因子C |
探针组代号 | 样品1 | 样品2 | 样品3 | 基因符号 | mRNA-登录号 | 平均值 | 标准偏差 |
2429144 | 14.42 | 14.47 | 14.51 | TRIM33 | NM_015906 | 14.5 | 0.05 |
2467968 | 13.90 | 13.90 | 14.10 | SOX11 | NM_003108 | 14.0 | 0.11 |
2431202 | 13.57 | 13.63 | 13.66 | NOTCH2 | NM_024408 | 13.6 | 0.05 |
2477142 | 13.19 | 13.25 | 13.18 | CRIM1 | NM_016441 | 13.2 | 0.04 |
2516866 | 12.80 | 12.91 | 12.91 | HOXD9 | NM_014213 | 12.9 | 0.07 |
2497821 | 12.41 | 12.59 | 12.37 | POU3F3 | NM_006236 | 12.5 | 0.12 |
分泌的蛋白质 |
β2微球蛋白 |
癌抗原19-9 |
肌酸激酶-MB |
ENA-78 |
内皮素-1 |
嗜伊红粒细胞趋化蛋白 |
脂肪酸结合蛋白 |
铁蛋白 |
碱性FGF |
IL-6 |
IL-8 |
胰岛素 |
MCP-1 |
PAI-1 |
干细胞因子 |
TIMP-1 |
VCAM-1 |
VEGF |
组编号 | 动物数目 | 植入物数目 | 试验材料 |
1 | 3 | 6 | 单独Matrigel |
2 | 3 | 6 | Matrigel+iMAC |
3 | 3 | 6 | Matrigel+bFGF |
Claims (7)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24722809P | 2009-09-30 | 2009-09-30 | |
US61/247228 | 2009-09-30 | ||
PCT/US2010/049850 WO2011041186A1 (en) | 2009-09-30 | 2010-09-22 | Mammary artery derived cells and methods of use in tissue repair and regeneration |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102639693A CN102639693A (zh) | 2012-08-15 |
CN102639693B true CN102639693B (zh) | 2015-08-12 |
Family
ID=43127664
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201080055145.1A Expired - Fee Related CN102639693B (zh) | 2009-09-30 | 2010-09-22 | 乳动脉衍生细胞及在组织修复和再生中的应用方法 |
Country Status (8)
Country | Link |
---|---|
US (2) | US8323972B2 (zh) |
EP (1) | EP2483393B1 (zh) |
JP (1) | JP5893562B2 (zh) |
CN (1) | CN102639693B (zh) |
AU (2) | AU2010300871B2 (zh) |
CA (1) | CA2781520C (zh) |
IN (1) | IN2012DN02760A (zh) |
WO (1) | WO2011041186A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8323972B2 (en) | 2009-09-30 | 2012-12-04 | Advanced Technologies And Regenerative Medicine, Llc | Mammary artery derived cells and methods of use in tissue repair and regeneration |
US8889413B2 (en) | 2009-09-30 | 2014-11-18 | DePuy Synthes Products, LLC | Mammary artery derived cells and methods of use in tissue repair and regeneration |
US8546338B2 (en) | 2010-12-08 | 2013-10-01 | Johnson & Johnson Consumer Companies, Inc. | Self-assembling hydrogels based on dicephalic peptide amphiphiles |
US20130209418A1 (en) * | 2012-02-15 | 2013-08-15 | Johnson & Johnson Regenerative Therapeutics, Llc | Methods and composition related to brown adipose-like cells |
KR102263824B1 (ko) * | 2014-07-11 | 2021-06-10 | 가부시키가이샤 메토세라 | 심장 세포 배양 재료 |
WO2018207783A1 (ja) * | 2017-05-08 | 2018-11-15 | 学校法人慶應義塾 | 多層構造体とその製造方法及び利用方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2646438B1 (fr) * | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
EP0546091B1 (en) | 1990-08-29 | 2007-01-24 | Pharming Intellectual Property BV | Homologous recombination in mammalian cells |
US5342761A (en) * | 1990-10-01 | 1994-08-30 | Research Development Foundation | Oncofetal gene, gene product and uses therefor |
US5286632A (en) * | 1991-01-09 | 1994-02-15 | Jones Douglas H | Method for in vivo recombination and mutagenesis |
WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
US5320962A (en) * | 1992-07-22 | 1994-06-14 | Duke University | DNA encoding the human A1 adenosine receptor |
WO2004019767A2 (en) | 2002-08-29 | 2004-03-11 | Baylor College Of Medicine | Heart derived cells for cardiac repair |
ES2265199B1 (es) | 2003-06-12 | 2008-02-01 | Cellerix, S.L. | Celulas madre adultas multipotentes procedentes de condrocitos desdiferenciados y sus aplicaciones. |
ATE494360T1 (de) | 2004-07-20 | 2011-01-15 | Univ Case Western Reserve | Neue zellpopulationen und deren anwendungen |
EP1781775B1 (en) * | 2004-07-28 | 2013-05-01 | Universite Paris Descartes | Vascular stem cells and uses thereof |
US20090124007A1 (en) * | 2006-11-15 | 2009-05-14 | Seoul National University Industry Foundation | Method for the Simultaneous Primary-Isolation and Expansion of Endothelial Stem/Progenitor Cell and Mesenchymal Stem Cell Derived From Mammal Including Human Umbilical Cord |
CA2723141A1 (en) * | 2008-04-30 | 2009-11-05 | Ethicon, Inc. | Tissue engineered blood vessel |
US8323972B2 (en) | 2009-09-30 | 2012-12-04 | Advanced Technologies And Regenerative Medicine, Llc | Mammary artery derived cells and methods of use in tissue repair and regeneration |
-
2010
- 2010-09-20 US US12/885,855 patent/US8323972B2/en active Active
- 2010-09-22 EP EP10760857.2A patent/EP2483393B1/en not_active Not-in-force
- 2010-09-22 CN CN201080055145.1A patent/CN102639693B/zh not_active Expired - Fee Related
- 2010-09-22 WO PCT/US2010/049850 patent/WO2011041186A1/en active Application Filing
- 2010-09-22 AU AU2010300871A patent/AU2010300871B2/en not_active Ceased
- 2010-09-22 CA CA2781520A patent/CA2781520C/en not_active Expired - Fee Related
- 2010-09-22 IN IN2760DEN2012 patent/IN2012DN02760A/en unknown
- 2010-09-22 JP JP2012532193A patent/JP5893562B2/ja not_active Expired - Fee Related
-
2012
- 2012-11-08 US US13/671,720 patent/US9650611B2/en active Active
-
2014
- 2014-07-02 AU AU2014203616A patent/AU2014203616B2/en not_active Ceased
Non-Patent Citations (2)
Title |
---|
Thoracic Aortas from Multiorgan Donors Are Suitable for Obtaining Resident Angiogenic Mesenchymal Stromal Cells;GIANANDREA PASQUINELLI et al.;《STEM CELLS》;20070731;第25卷;第1629-1631页 * |
Vascular wall resident progenitor cells: a source for postnatal vasculogenesis;Zengin E, et al.;《Development》;20060308;第133卷;第1543-1551页 * |
Also Published As
Publication number | Publication date |
---|---|
AU2014203616A1 (en) | 2014-07-17 |
US8323972B2 (en) | 2012-12-04 |
US20110076769A1 (en) | 2011-03-31 |
AU2010300871B2 (en) | 2014-09-25 |
AU2010300871A1 (en) | 2012-05-03 |
IN2012DN02760A (zh) | 2015-09-18 |
AU2014203616B2 (en) | 2015-10-01 |
JP2013506420A (ja) | 2013-02-28 |
CA2781520C (en) | 2018-12-04 |
EP2483393B1 (en) | 2018-08-08 |
CN102639693A (zh) | 2012-08-15 |
JP5893562B2 (ja) | 2016-03-23 |
WO2011041186A1 (en) | 2011-04-07 |
US20130065305A1 (en) | 2013-03-14 |
US9650611B2 (en) | 2017-05-16 |
CA2781520A1 (en) | 2011-04-07 |
EP2483393A1 (en) | 2012-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kelm et al. | Scaffold-free cell delivery for use in regenerative medicine | |
Caron et al. | A new three dimensional biomimetic hydrogel to deliver factors secreted by human mesenchymal stem cells in spinal cord injury | |
Rivron et al. | Engineering vascularised tissues in vitro | |
Bernstein et al. | Stem cell therapy for cardiac disease | |
US11045502B2 (en) | Method of isolating cells for therapy and prophylaxis | |
CN102639693B (zh) | 乳动脉衍生细胞及在组织修复和再生中的应用方法 | |
Colazzo et al. | Shear stress and VEGF enhance endothelial differentiation of human adipose-derived stem cells | |
AU2002360741B2 (en) | Endothelial stem cells, populations, methods of isolation and use thereof | |
Liang et al. | Gelatin methacryloyl-alginate core-shell microcapsules as efficient delivery platforms for prevascularized microtissues in endodontic regeneration | |
CN101148656B (zh) | 一种组织工程化肝单元的构建方法 | |
Alves da Silva et al. | Electrospun nanofibrous meshes cultured with Wharton's jelly stem cell: an alternative for cartilage regeneration, without the need of growth factors | |
Sun et al. | Isolation of ready-made rat microvessels and its applications in effective in vivo vascularization and in angiogenic studies in vitro | |
Priya et al. | Accelerating vascular graft development: Adipose-derived stem cells and PODS®(Polyhedrin delivery system with tissue-specific growth factors)–Enhanced 3D bioprinting for functional blood vessels | |
US8889413B2 (en) | Mammary artery derived cells and methods of use in tissue repair and regeneration | |
US12005157B2 (en) | Isolation and co-transplantation of bone marrow mesenchymal stem cells with CD34+ hematopoietic stem/progenitor cells | |
Zhang | Autologous cell sources for urological applications | |
WO2019175459A1 (es) | Células precursoras multipotentes obtenidas del músculo cremáster y su uso en el desarrollo de terapias y medicina regenerativa | |
Twardowski | Cardiac Fibroblasts as a Support for Endothelial Cell Sprout Formation in Engineered Cardiac Tissue | |
Uzarski | In vitro endothelialization and shear conditioning of decellularized vascular allografts | |
CN105106239A (zh) | 使用产后衍生细胞治疗外周血管疾病 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HAND INNOVATIONS LLC Free format text: FORMER OWNER: DEPUY SPINE INC. Effective date: 20140702 Owner name: DEPUYI ORTHOPEDIC COMPANY Free format text: FORMER OWNER: ADVANCED TECHNOLOGIES AND REGE Effective date: 20140702 Owner name: DEPUY SPYER CORP. Free format text: FORMER OWNER: DEPUYI ORTHOPEDIC COMPANY Effective date: 20140702 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: Massachusetts, USA Applicant after: DEPUY SYNTHES PRODUCTS, LLC Address before: American Florida Applicant before: HAND INNOVATIONS, LLC Address after: Massachusetts, USA Applicant after: Depp Speyer Iraq LLC Address before: Massachusetts, USA Applicant before: DEPUY SPINE, Inc. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: DEPUY SPYER CORP. TO: DEPUY SPINE INC. Free format text: CORRECT: APPLICANT; FROM: HAND INNOVATIONS LLC TO: DEPUY SYNTHES PRODUCTS LLC |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20140702 Address after: American Florida Applicant after: HAND INNOVATIONS, LLC Address before: Massachusetts, USA Applicant before: Depp Speyer Iraq LLC Effective date of registration: 20140702 Address after: Massachusetts, USA Applicant after: DEPUY SPINE, Inc. Address before: indiana Applicant before: Depp Iraq orthopedic Co. Effective date of registration: 20140702 Address after: indiana Applicant after: Depp Iraq orthopedic Co. Address before: Massachusetts, USA Applicant before: ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150812 |